rofecoxib
Quizzes for review
(pharmacology) A COX-2 inhibitor C₁₇H₁₄O₄S (trademark Vioxx) used to relieve the signs and symptoms of osteoarthritis and rheumatoid arthritis, to manage acute pain in adults, and to treat primary dysmenorrhea but withdrawn from sale by the manufacturer because of its link to cardiovascular events (as heart attack and stroke).
rofecoxib
After reviewing the clinical data, the committee concluded that rofecoxib posed an unacceptable cardiovascular risk and recommended its withdrawal from the market.
After reviewing the clinical data, the committee concluded that rofecoxib posed an unacceptable cardiovascular risk and recommended its withdrawal from the market.
English - English
- Users who have edit permission for words - All Users
- Screen new word creation
- Screen word edits
- Screen word deletion
- Screen the creation of new headword that may be duplicates
- Screen changing entry name
- Users authorized to vote on judging - Editor
- Number of votes required for decision - 1
- Users who have edit permission for sentences - All Users
- Screen sentence deletion
- Users authorized to vote on judging - Editor
- Number of votes required for decision - 1
- Users who have edit permission for quizzes - All Users
- Users authorized to vote on judging - Editor
- Number of votes required for decision - 1